Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

a macrophage migration and inhibitory factor technology, applied in the direction of antibacterial agents, immunological disorders, metabolism disorders, etc., can solve the problems of limited ability to evaluate the inhibition of mif to its cell surface receptor, significant toxicity, and toxicity of inhibitors that act intracellularly

Inactive Publication Date: 2007-03-08
AVANIR PHARMA
View PDF43 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] As MIF has been identified in a variety of tissues and has been associated with numerous pathological events, there exists a need in the art to identify inhibitors of MIF. There is also a need for pharmaceutical compositions containing such inhibitors, as well as methods relating to the use thereof to treat, for example, immune related disorders or other MIF induced pathological events, such as tumor associated angiogenesis. The preferred embodiments may fulfill these needs, and provide other advantages as well.
[0027] In a third embodiment, a method is provided for reducing MIF activity in a patient in need thereof, comprising administering to the patient an effective amount of a compound having the structure: or a stereoisomer, a prodrug, or a pharmaceutically acceptable salt thereof.

Problems solved by technology

Hence, when its activities / gene expression are overinduced by the administration of excess exogenous glucocorticoids (for example when clinical indicated to suppress inflammation, immunity and the like), there is significant toxicity because MIF itself exacerbates the inflammatory / immune response.
Further, it remains unclear whether this enzymatic activity mediates the biological response to MIF and the activities of this protein in vitro and in vivo.
The ability to evaluate the inhibition of MIF to its cell surface receptor is also limited since no high affinity receptor is currently known.
Furthermore, inhibitors that act intracellularly are often toxic by virtue of their action on related targets or the activities of the target inside cells.
Small molecule inhibitors of the ligand receptor complex are difficult to identify let alone optimize and develop.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  • Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  • Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0175] Macrophage Migration Assay

[0176] Macrophage migration is measured by using the agarose droplet assay and capillary method as described by Harrington and Stastny et al., J. Immunol. 110(3):752-759, 1973. Briefly, macrophage-containing samples are added to hematocrit tubes, 75 mm long with a 1.2 mm inner diameter. The tubes are heat sealed and centrifuged at 100×G for 3 minutes, cut at the cell-fluid interface and imbedded in a drop of silicone grease in Sykes-Moore culture chambers. The culture chambers contain either a control protein (BSA) or samples. Migration areas are determined after 24 and 48 hours of incubation at 37° C. by tracing a projected image of the macrophage fans and measuring the areas of the migration by planimetry.

[0177] Alternatively, each well of a 96-well plate is pre-coated with one microliter of liquid 0.8% (w / v) Sea Plaque Agarose in water dispensed onto the middle of each well. The plate is then warmed gently on a light box until the agarose drops ...

example 2

[0219] Inhibitors of MIF of certain embodiments may be prepared according to the following reaction schemes. Each of these MIF inhibitors belongs to one of the classes of compounds described above. The variables R1, R2, R3, R4, Z, and n are as defined above.

[0220] General Methods for the Synthesis of the Compounds of the Inventions

[0221] The compounds were synthesized starting from substituted or unsubstituted isatoic anhydrides. The strategies to introduce R2 and / or R3 groups into the compounds of structures (1a) and (1b) described above involved preparation of substituted isatoic anhydrides as precursor compounds from substituted anthranilic acids. The substituted anthranilic acids were prepared from substituted nitrobenzoic acids. In some cases, the nitro benzoic acids were obtained by nitration of appropriate benzoic acid, as shown in Reaction Scheme 1, however, any suitable method for preparation of nitrobenzoic acids may be employed.

[0222] Two different methods were employ...

example 3

[0231] The following describes the synthesis of a library of compounds of general structure 1′(a) and 1′(b) as depicted below. Compounds including “M” in the designation incorporate the CN moiety. Numerical designations in Table 1 are as given below.

[0232] In compounds that have designations including “+i”, R,13 is a substituent on the oxygen atom of the quinolone group rather than the nitrogen atom, i.e., a compound of structure 1′(b), as depicted below. The designation “i” appears elsewhere in the preferred embodiments, and refers to a substituent on the oxygen atom of the quinolone group rather than the nitrogen atom.

Numerical Designations for R11 Functional Groups

[0233]

HydrogenMethylChlorine123

Numerical Designations for R12 Functional Groups

[0234]

Numerical Designations for R13 Functional Groups

[0235]

[0236] The numerical designations of the MIF inhibitors prepared are provided in Table 1.

TABLE 1R13 = 1R13 = 2R13 = 4R13 = 5R13 = 6Methyl1M111M121M131M141M15 + i1M211M221M231...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular massaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a division of U.S. application Ser. No. 10 / 778,884 filed Feb. 13, 2004, which claims the benefit of U.S. Provisional Application No. 60 / 448,427, filed Feb. 14, 2003.FIELD OF THE INVENTION [0002] This invention relates generally to inhibitors of macrophage migration inhibitory factor (MIF), methods for identifying MIF inhibitors, and to methods of treating MIF-related disorders by administration of such inhibitors. BACKGROUND OF THE INVENTION [0003] The lymphokine, macrophage migration inhibitory factor (MIF), has been identified as a mediator of the function of macrophages in host defense and its expression correlates with delayed hypersensitivity, immunoregulation, inflammation, and cellular immunity. See Metz and Bucala, Adv. Immunol. 66:197-223, 1997. Macrophage migration inhibitory factors (MIFs), which are between 12-13 kilodaltons (kDa) in size, have been identified in several mammalian and avian species; see, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/497A61K31/4709C07D403/14A61KA61K31/496A61P29/00A61P35/00C07CC07D215/54C07D401/04C07D401/12C07D405/12C07D409/12C07D413/12C07D417/12
CPCA61K31/496A61K31/52A61K31/54A61K31/56C07D417/12C07D401/12C07D405/12C07D409/12C07D413/12C07D215/54A61P1/00A61P1/04A61P3/10A61P9/00A61P11/00A61P11/06A61P19/02A61P25/00A61P29/00A61P31/04A61P35/00A61P37/00A61P37/06A61P37/08A61P43/00C07D401/04
Inventor SIRCAR, JAGADISHK C, SUNILYING, WENBIN
Owner AVANIR PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com